Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Moderately severe Alzheimer disease Clinical criteria: Treatment Phase: Initial Patient must have a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 10 to 14, AND The condition must be confirmed by, or in consultation with, a specialist/consultant physician (including a psychiatrist), AND The treatment must be the sole PBS-subsidised therapy for this condition. The authority application must include the result of the baseline MMSE or SMMSE of 10 to 14. Up to a maximum of 6 months' initial therapy will be authorised for this drug, for this strength under this treatment restriction.
“Memantine is a rapid, strongly voltage-dependent, uncompetitive NMDA receptor antagonist.”
“Memantine is eliminated predominantly by the kidneys in a monoexponential manner with a terminal half-life of 60 to 100 h.”
“In vitro experiments have indicated that memantine is not metabolised by CYP isoenzymes 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1 and 3A4.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.